NASDAQIndustrialsIntegrated Freight & LogisticsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CJMB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise equity capital | A supporting condition in CALLAN JMB INC's published investment case. The stated target is Raise at least $5 million in equity by 2026-Q3. | Improving | Fail to raise $5M equity by 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business with a volatile management profile, not an established compounder. The long-term thesis is in watch status, and the evidence points to a weak operating base that still needs to show improvement.
The valuation evidence describes CJMB as cheap versus peers, but confidence in that comparison is low. The snapshot does not show which business expectations the market already assumes, so the expectations gap is unclear.
Near term, recent financial performance is weak relative to its industry cohort, while improving operating income and cash from operations remain management priorities to watch. The delisting notice adds a listing-compliance risk, despite two recent acquisition announcements; the evidence does not establish their financial impact.
Over the next one to three years, the thesis hinges on better operating income and cash generation, progress on Nasdaq listing compliance, and whether the acquisitions support the business. The sector backdrop is a headwind: stronger results from UPS, FDX, and EXPD could support Industrials sentiment, while weaker jobs data or bellwether results could weigh on cyclical businesses like CJMB.
The multi-year view is uncertain: CJMB is loss-making, execution needs improvement, and listing compliance is an added concern. Recent acquisitions and a low-confidence valuation comparison offer limited counterweight to the weak fundamentals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in CALLAN JMB INC's published investment case. The stated target is Positive cash from operations by 2027-Q2. |
| Improving |
| Cash flow remains negative beyond 2027-Q2 |
Cash from operations: $-396,063 FY2026-Q2; GAAP. Published target: Positive cash from operations by 2027-Q2. The stored target says 2027-Q2; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-396,063 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve Nasdaq listing deficiencies | Callan JMB is working to fix its Nasdaq listing problems and improve its operating income. | Improving | Nasdaq delisting or failure to cure deficiencies by 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses | Callan JMB is working to fix its Nasdaq listing problems and improve its operating income. | Intact | Operating loss remains worse than -$1.7M beyond 2026-Q4 | Operating income: $-1.347M FY2026-Q2; GAAP. Published target: Operating loss narrows to less than -$1.0M by 2026-Q4. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-1,346,646 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.